Kenneth R. Deans Jr.
South Carolina
Kenneth R. Deans Jr. is a Contributing Writer for The American Quorum. With 30+ years of leadership across healthcare, technology, and education, he brings an experienced, independent perspective to issues shaping America.
Healthcare
CDC Adds COVID-19 Vaccination to 2023 Routine Immunization Schedules for Children and Adults
Tech
Microsoft Puts OpenAI Technology Into Bing as Google Unveils Bard, Turning Generative AI Into a Search War
Healthcare
Biden Administration Sets May 11 End for COVID-19 Emergencies, Beginning a 100-Day Health-System Transition
Tech
Meta Revenue Falls 4% as Reality Labs Loses $4.28 Billion and Zuckerberg Declares a ‘Year of Efficiency’
Healthcare
FDA Advisers Vote 21-0 to Align COVID-19 Primary and Booster Vaccines Around a Single Strain Composition
Tech
DOJ and Eight States Sue Google Over Digital Advertising, Alleging a 15-Year Monopoly Campaign
Healthcare
Phase 3 Mosaico HIV Vaccine Trial Stops After 3,900-Participant Study Finds No Protection Against Infection
Tech
Google Cuts 12,000 Jobs, About 6% of Workforce, as Pichai Resets Costs After Pandemic Hiring Boom
Healthcare
HHS Renews COVID-19 Public Health Emergency for Another 90 Days as Federal Flexibilities Remain in Place
Tech
Microsoft Weighs Reported $10 Billion OpenAI Investment as ChatGPT Pushes Generative AI Into Big-Tech Race
Healthcare
FDA Grants Accelerated Approval to Leqembi for Early Alzheimer’s, Pairing Amyloid Reduction With New Safety and Access Questions
Tech
Amazon Expands Layoffs to More Than 18,000 Roles, Largest Workforce Reduction in Company History
Healthcare
U.S. Orders COVID-19 Tests for Travelers From China as Officials Cite Data Gaps and Variant Surveillance
Tech
U.S. Bans TikTok on Federal Devices as Congress Turns Security Concerns Into Law
Healthcare
FDA Approves Actemra for Hospitalized Adults With Severe COVID-19 After RECOVERY Shows 29% vs. 33% 28-Day Mortality
Tech
Epic Games Agrees to $520 Million FTC Settlement Over Children’s Privacy and Fortnite Billing Practices
Healthcare
FDA Grants Accelerated Approval to Krazati After 42.9% Response Rate in KRAS G12C-Mutated Lung Cancer
401 stories